AI Science Tracker

University of Michigan

2 discoveries from 2020 to 2021

Discoveries

Retrosynthetic software finds experimentally validated supply routes for umifenovir

Retrosynthesis software proposed alternative chemical supply routes for the antiviral umifenovir and eleven other antiviral and anti-inflammatory drugs. The authors experimentally validated four routes to umifenovir and one route to bromhexine, one of which converts six C-H bonds. The work is a proof of route feasibility for supply-chain resilience, not a new therapeutic claim.

Technology: Computer-aided retrosynthesis software with exclusion of known starting materials

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: The authors experimentally validated four routes to umifenovir and one route to bromhexine proposed by the software.
  • Still unknown: Not reported.
  • AI role: Retrosynthesis software proposed alternative supply routes for umifenovir and other antiviral and anti-inflammatory drugs.

Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41467-021-27547-3&resultType=core&format=json

The legacy label “Not reported” does not distinguish information absent from reviewed material from information not assessed. It is not a scientific finding of absence.

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: at percentile 87 of works of the same type, year and subfield (OpenAlex work metrics, 38 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Deep neural networks diagnose brain tumours in minutes from stimulated Raman histology

CNNs trained on over 2.5 million stimulated Raman histology images produced intraoperative brain tumour diagnoses in under 150 seconds, with 94.6% accuracy versus 93.9% for pathologists. The accuracy comparison comes from a prospective multicentre trial with 278 patients, but the abstract does not report sensitivity or specificity separately.

Technology: Deep neural networks on stimulated Raman histology images

Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: prospective or independent check
  • Tested: Multicenter prospective clinical trial (n = 278): CNN diagnosis of stimulated Raman images was non-inferior to pathologists reading conventional histology (94.6% versus 93.9%), in under 150 seconds.
  • Still unknown: Long-term patient outcomes are not reported in the abstract.
  • AI role: Convolutional neural networks trained on over 2.5 million stimulated Raman histology images.

Evidence sources: https://doi.org/10.1038/s41591-019-0715-9

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 839 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 4/5 · Validation 4/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.